CSL Behring

CSL Behring
Name	CSL Behring
Type	Subsidiary
Industry	Biopharmaceuticals
Founded	1904 (Behringwerke origins)
Headquarters	King of Prussia, Pennsylvania, United States; Melbourne, Australia (CSL Limited)
Area served	Global
Key people	Paul Perreault (CEO, CSL), David Lamont (President, CSL Behring)
Products	Plasma-derived and recombinant therapeutics for immunology, hematology, respiratory disease
Parent	CSL Limited
Employees	~25,000 (CSL group)

CSL Behring CSL Behring is a global biopharmaceutical company specializing in plasma-derived and recombinant therapies for rare and serious diseases. Founded through the convergence of historical entities from the early twentieth century and consolidated under an Australian parent, the company operates across multiple continents with a focus on immunodeficiency, hematology, and critical care. CSL Behring engages in research, development, manufacturing, and distribution while participating in public health initiatives and collaborations with academic, clinical, and industry partners.

History

The company's antecedents trace to pioneers such as Emil von Behring, whose work on antitoxins influenced institutions like the Behringwerke and later enterprises merged into the present organization. Over the twentieth century, mergers and acquisitions connected entities including CSL Limited, ZLB Bioplasma, Baxter International, Aventis Behring, and Sankyo-linked operations, while regulatory milestones involved agencies like the U.S. Food and Drug Administration, European Medicines Agency, and national authorities in Australia, Germany, and the United States. Strategic acquisitions such as purchases from Baxalta and collaborations with companies like Novartis and Takeda Pharmaceutical Company expanded the portfolio and global footprint. Corporate actions intersected with events including the global response to pandemics and the evolution of plasma collection standards influenced by organizations such as the World Health Organization and the Centers for Disease Control and Prevention.

Products and Therapeutic Areas

CSL Behring's portfolio includes plasma-derived products like immunoglobulins, albumin, and clotting factor concentrates, alongside recombinant products and specialty drugs targeting rare disorders. Key therapeutic areas encompass immunodeficiency disorders treated with intravenous and subcutaneous immunoglobulin therapies used in clinical settings alongside protocols from institutions such as Mayo Clinic and Johns Hopkins Hospital. Hematology offerings address hemophilia and von Willebrand disease with factor concentrates developed in contexts involving regulatory submissions to the European Commission and trials guided by standards from groups like the World Federation of Hemophilia. Respiratory and critical care products serve patients in intensive care units at centers such as Massachusetts General Hospital and Royal Melbourne Hospital. The company also produces vaccines and antitoxins relevant to biodefense and public health, engaging with stakeholders including Gavi, the Vaccine Alliance and national immunization programs.

Research and Development

R&D at CSL Behring spans basic science collaborations, translational programs, and clinical trials conducted in partnership with academic centers like Harvard Medical School, University of Oxford, Karolinska Institutet, and University of Tokyo. Development pipelines incorporate monoclonal antibodies, recombinant clotting factors, gene therapy adjuncts, and next-generation immunoglobulin formulations, leveraging platforms used across biopharma innovators such as Genentech, Roche, Amgen, and Biogen. Clinical development follows phases overseen by ethics committees and regulatory agencies including the U.S. National Institutes of Health trial registries and the European Medicines Agency procedures, with endpoints informed by disease registries maintained by organizations like the European Haemophilia Network. Collaborative programs with foundations such as the Bill & Melinda Gates Foundation and disease-specific nonprofits including Haemophilia Foundation chapters support research into global access and epidemiology.

Manufacturing and Global Operations

Manufacturing operations combine plasma collection networks, fractionation plants, and aseptic fill-finish facilities located across regions including North America, Europe, and Asia-Pacific. Operational sites adhere to standards from regulatory bodies such as the U.S. Food and Drug Administration, Therapeutic Goods Administration (Australia), and Paul-Ehrlich-Institut in Germany, and employ quality systems comparable to peers like Baxter International and Grifols. Supply chain resilience strategies reflect lessons from global events involving logistics partners such as DHL and FedEx, and collaboration with healthcare systems including NHS England and Medicare providers to deliver plasma-derived therapies. Investments in capacity expansion have paralleled efforts by industry players including Takeda and Shire to meet demand for orphan and specialty products.

Corporate Governance and Ownership

CSL Behring operates as a subsidiary of CSL Limited, whose board and executive leadership include figures experienced in pharmaceuticals and biotechnology. Governance frameworks align with corporate practices common to listed companies on the Australian Securities Exchange, incorporating audit committees, risk management policies, and compliance functions interacting with regulators like the Australian Securities and Investments Commission and the U.S. Securities and Exchange Commission. Strategic decisions have involved engagement with institutional investors such as BlackRock, Vanguard Group, and Fidelity Investments, while philanthropic and CSR initiatives partner with entities like the Red Cross and patient advocacy groups including Global Genes.

Market Presence and Financial Performance

CSL Behring competes in global specialty pharmaceutical markets alongside companies such as Takeda Pharmaceutical Company, Grifols, Baxalta, Octapharma, and Shire (pre-acquisition entities). Revenue and profitability trends reflect demand for plasma therapies, orphan drugs, and vaccine-related products, with financial reporting consolidated into CSL Limited results presented to shareholders and analysts covering indices like the S&P/ASX 200. Market dynamics are influenced by pricing debates involving payers such as Centers for Medicare & Medicaid Services and national health services, while strategic growth has been driven by mergers, licensing deals, and investments in R&D and manufacturing capacity mirroring sector behavior exemplified by Pfizer and Sanofi.

Category:Biopharmaceutical companies